GMAB Stock Analysis: Buy, Sell, or Hold?
GMAB - Genmab A/S ADS
$25.87
-0.08 (-0.29%)
▼
5d:
+4.55%
30d:
-3.74%
90d:
+0.21%
BUY
HIGH Confidence
Analysis Updated: Jun 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Get Alerted When GMAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GMAB trading at deep discount. Market pricing in -5.6% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: GMAB trading at deep discount. Market pricing in -5.6% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$59.89
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$37.18
30.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMAB is currently trading at $25.86, which is considered fair relative to its 30-day fair value range of $24.63 to $26.55. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.1) compared to its historical average (16.8). Remarkably, the market is currently pricing in an annual earnings decline of 5.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GMAB is in a downtrend. The price is approaching resistance at $26.24. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GMAB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $36.82 (+42.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GMAB is in a downtrend. The price is approaching resistance at $26.24. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: GMAB has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $36.82 (+42.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$24.63 -
$26.55
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
83.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 42.3% below Wall St target ($36.82)
Trading Range Analysis
30-Day Trading Range
$24.63 -
$26.55
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$24.09
Resistance Level
$26.24
Current Trend
Downtrend
Technical data as of
Jun 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.13
Wall Street Target
$36.82
(+42.3%)
Revenue Growth (YoY)
25.3%
Earnings Growth (YoY)
-72.8%
Profit Margin
21.1%
Valuation Discount vs History
-5.6% cheaper
PE vs Historical
14.1 vs 16.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.6%
(market-implied from PE analysis)
1-Year Target
$24.42
(-6%)
2-Year Target
$23.05
(-11%)
3-Year Target
$21.76
(-16%)
3-Yr Target (if PE normalizes)
(PE: 14→17)
$25.87
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 75.8%)
$134.56
(+420%)
Base:
(SPY PE: 14.1, Growth: 75.8%)
$87.29
(+238%)
Bear:
(PE: 12.0, Growth: 75.8%)
$74.20
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (20x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 19.65 | Current EPS (TTM): $1.32
Bull Case
$39.57
(+53%)
Analyst growth 38.7%, PE expands to 21.6
Base Case
$35.97
(+39%)
Market implied 38.7%, PE stable at 19.7
Bear Case
$17.64
(-32%)
Severe decline -20.0%, PE contracts to 16.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.1 to 16.8
Stabilization Target:
$30.75
(+18.9%)
PE Expansion Potential:
+18.9%
Share & Embed Analysis
Last updated: June 24, 2026 7:09 PM ET
Data refreshes hourly during market hours. Next update: 8:09 PM
Data refreshes hourly during market hours. Next update: 8:09 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 57 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
